Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (V) domain, a TCR variable beta domain (V) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.

Engineered TCR molecules specific to retroviral peptide/HLA complexes guide direct killing and/or enable robust immune responses against HIV infected cells. In a first aspect, a TCR fusion polypeptide comprises a TCR variable alpha (V) domain, a TCR variable beta domain (V) and a TCR constant region domain (C), wherein the TCR fusion polypeptide is specific for HIV peptides.

The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.

The present disclosure provides compositions and methods that rapidly and selectively modify cells of the immune system to achieve therapeutic objectives. The methods can be practiced in vivo and any cell type that expresses a known marker can be targeted for a therapeutic objective.

Provided are chimeric antigen receptors (CARs) comprising an NGK2D ecto domain. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.

Provided are chimeric antigen receptors (CARs) comprising an NGK2D ecto domain. Provided are compositions, cells and cell therapies comprising the same. Further provided are methods of treatment.

Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing soluble IL-15/IL-15R complexes ex vivo, in cell culture during ex vivo sensitizing of T cells to the antigen or during ex vivo culturing of antigen-specific T cells. Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells. Cell culture systems comprising human T cells, antigen-presenting cells, and soluble IL-15/IL-15R complexes are also provided.

Provided herein are methods of generating antigen-specific T cells for therapeutic administration to a human patient having or suspected of having a pathogen or cancer, utilizing soluble IL-15/IL-15R complexes ex vivo, in cell culture during ex vivo sensitizing of T cells to the antigen or during ex vivo culturing of antigen-specific T cells. Also disclosed are antigen-specific T cells generated by such methods, and methods of treating a human patient using such antigen-specific T cells. Cell culture systems comprising human T cells, antigen-presenting cells, and soluble IL-15/IL-15R complexes are also provided.

Provided is a pharmaceutical composition or combination comprising: (i) an isolated population of cells comprising V17+CD8+ T cells, (ii) one or more T cell engagers; and (iii) a pharmaceutically acceptable excipient. Also provided are methods of using the isolated population of cells comprising V17+CD8+ T cells and the T cell engagers for redirecting a T cell to a target cell, inhibiting the growth or proliferation of a target cell, eliminating a target cell, or treating a disease or disorder.

Provided is a pharmaceutical composition or combination comprising: (i) an isolated population of cells comprising V17+CD8+ T cells, (ii) one or more T cell engagers; and (iii) a pharmaceutically acceptable excipient. Also provided are methods of using the isolated population of cells comprising V17+CD8+ T cells and the T cell engagers for redirecting a T cell to a target cell, inhibiting the growth or proliferation of a target cell, eliminating a target cell, or treating a disease or disorder.